Quantcast

Latest TYSABRI Stories

2010-04-16 14:06:55

Data also showed reduced fatigue and improved cognition Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measured by validated tools. The goal of the study, which was...

2010-03-01 09:02:00

WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018. While some drugs in development for multiple sclerosis hold promise, most have less favorable efficacy and/or delivery features compared with Tysabri....

2009-11-30 13:48:16

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis. The panel provided recommendations focusing on appropriate patient selection and patient management. The recommendations, which recognize the significant efficacy of TYSABRI and the need to adequately treat patients...

2009-09-12 16:46:10

Results further support the benefits of TYSABRI for multiple sclerosis patients Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in...

2009-07-30 15:02:00

INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter ended June 30, 2009. Total revenues from continuing operations for the second quarter of 2009 were $125.9 million, an 18 percent increase from $106.5 million for the same period in 2008. The increase was due primarily to royalty revenues driven by higher product sales of Avastin(R), and Lucentis(R), which are marketed by Genentech,...

2009-02-04 07:00:00

Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States,...

7d6c5e2a2a65ac0a0e019d7364038c9d1
2008-12-15 14:42:08

On Monday, Biogen Idec Inc said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year. Biogen stated in a regulatory filing that the latest case of the brain infection, known as progressive multifocal leukoencephalopathy (PML), was seen in a European patient that had been taking Tysabri as a stand-alone treatment for 26 months. Company spokeswoman Shannon...

2008-11-03 12:00:26

PatientsLikeMe, the leading online community for patients with life-changing conditions, announces the release of its newest PatientsLikeMeListen(TM) report: "Did the July 2008 PML announcement affect the Tysabri brand?" Among its findings, the report reveals that patients retained an overall positive perception of the Tysabri brand despite the July 2008 announcement of two additional PML cases. "In light of last week's announcement of an additional case of PML in a Tysabri patient, we felt...

2008-10-31 00:00:20

Biogen Idec Inc. says a U.S. woman contracted a deadly brain infection while taking the drug Tysabri. The drug maker said the woman contracted progressive multifocal leukoencephalopathy, or PML, while taking the drug alone rather than in conjunction with other drugs, The Wall Street Journal reported Thursday. The U.S. Food and Drug Administration said in August that using Tysabri alone may confer a lower risk of PML than when the drug is used together with other immunomodulatory...

2008-10-06 12:00:43

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success http://www.reportlinker.com/p095770/Commercial-Insight-Inflammatory-Bowel-Disease---Convenience-and-compliance-drive-market-success.html Introduction Several product launches and indication expansion caused substantial sales growth in the seven major...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related